The main goal of this study is to determine the effects of combination medical therapy (Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and right ventricular (RV) function (including advanced assessments of RV-pulmonary artery (PA) coupling from invasive hemodynamics) in participants with inoperable or post-PTE residual CTEPH.
Age ≥ 18 years' old
Diagnosis of CTEPH
Not a candidate for PTE
Candidate for BPA based on suitable anatomy and disease burden
Moderate to severe heart disease (LVEF < 45% or severe LV Hypertrophy)
Sarcoidosis
Active cancer
Sickle cell anemia
Dr Sudarshan Rajagopal
Lead sponsor
Duke University
Sponsor institution
Janssen Pharmaceutica N.V., Belgium
Collaborator